Biology Reference
In-Depth Information
168. Yacoub A, Kelley MR, Deutsch WA. The DNA repair activity of
human redox/repair protein APE/Ref-1 is inactivated by phos-
phorylation.
Cancer Res
1997;
190. Gao Z, et al. Inhibitors of DNA polymerase beta: activity and
mechanism.
Bioorg Med Chem
2008;
40.
191. Barakat K, Tuszynski J. Relaxed complex scheme suggests novel
inhibitors for the lyase activity of DNA polymerase beta.
JMol
Graph Model
2011;
16
(8):4331
e
9.
169. Fritz G, Kaina B. Phosphorylation of the DNA repair protein
APE/REF-1 by CKII affects redox regulation of AP-1.
Oncogene
1999;
57
(24):5457
e
15.
192. Hu HY, et al. Identification of small molecule synthetic inhibitors
of DNA polymerase beta by NMR chemical shift mapping.
J Biol
Chem
2004;
29
:702
e
40.
170. Huang E, et al. The role of Cdk5-mediated apurinic/apyrimidinic
endonuclease 1 phosphorylation in neuronal death.
Nat Cell Biol
2010;
18
(4):1033
e
44.
193. Martin SA, et al. DNA polymerases as potential therapeutic
targets for cancers deficient in the DNA mismatch repair proteins
MSH2 or MLH1.
Cancer Cell
2010;
279
(38):39736
e
71.
171. Nakayama KI, Nakayama K. Ubiquitin ligases: cell-cycle control
and cancer.
Nat Rev Cancer
2006;
12
(6):563
e
81.
172. Chau V, et al. A multiubiquitin chain is confined to specific lysine
in a targeted short-lived protein.
Science
1989;
6
(5):369
e
48.
194. Larsen E, et al. Organ and cell specificity of base excision repair
mutants in mice.
Mutat Res
2007;
17
(3):235
e
83.
173. Nijman SM, et al. A genomic and functional inventory of deu-
biquitinating enzymes.
Cell
2005;
243
(4898):1576
e
68.
195. Fishel ML, Kelley MR. The DNA base excision repair protein
Ape1/Ref-1 as a therapeutic and chemopreventive target.
Mol
Aspects Med
2007;
614
(1-2):56
e
86.
174. Busso CS, Iwakuma T, Izumi T. Ubiquitination of mammalian AP
endonuclease (APE1) regulated by the p53-MDM2 signaling
pathway.
Oncogene
2009;
123
(5):773
e
95.
196. Abbotts R, Madhusudan S. Human AP endonuclease 1 (APE1):
from mechanistic insights to druggable target in cancer.
Cancer
Treat Rev
2010;
28
(3-4):375
e
25.
175. Qu J, et al. Nitric oxide controls nuclear export of APE1/Ref-1
through S-nitrosation of cysteines 93 and 310.
Nucleic Acids Res
2007;
28
(13):1616
e
35.
197. Ono Y, et al. Stable expression in rat glioma cells of sense and
antisense nucleic acids to a human multifunctional DNA repair
enzyme, APEX nuclease.
Mutat Res
1994;
36
(5):425
e
32.
176. Fan Z, et al. Cleaving the oxidative repair protein Ape1 enhances
cell death mediated by granzyme A.
Nat Immunol
2003;
35
(8):2522
e
63.
198. Bobola MS, et al. Apurinic/apyrimidinic endonuclease activity is
associated with response to radiation and chemotherapy in
medulloblastoma and primitive neuroectodermal tumors.
Clin
Cancer Res
2005;
315
(1):55
e
4
(2):
53.
177. Chattopadhyay R, et al. Identification and characterization of
mitochondrial abasic (AP)-endonuclease in mammalian cells.
Nucleic Acids Res
2006;
145
e
14.
199. Yang ZZ, Chen XH, Wang D. Experimental study enhancing the
chemosensitivity of multiple myeloma to melphalan by using
a tissue-specific APE1-silencing RNA expression vector.
Clin
Lymphoma Myeloma
2007;
11
(20):7405
e
76.
178. Li M, et al. Identification and characterization of mitochondrial
targeting sequence of human apurinic/apyrimidinic endonu-
clease 1.
J Biol Chem
2010;
34
(7):2067
e
81.
179. Meynard D, et al. Functional analysis of the gene expression
profiles of colorectal cancer cell lines in relation to oxaliplatin and
cisplatin cytotoxicity.
Oncol Rep
2007;
285
(20):14871
e
304.
200. Zhang Y, et al. Alterations in the expression of the apurinic/
apyrimidinic endonuclease-1/redox factor-1 (APE1/Ref-1) in
human ovarian cancer and indentification of the therapeutic
potential of APE1/Ref-1 inhibitor.
Int J Oncol
2009;
7
(4):296
e
21.
180. Jiang Y, et al. Implications of apurinic/apyrimidinic endonu-
clease in reactive oxygen signaling response after cisplatin treat-
ment of dorsal root ganglion neurons.
Cancer Res
2008;
17
(5):1213
e
79.
201. Lau J, et al. Effects of gemcitabine on APE/ref-1 endonuclease
activity in pancreatic cancer cells, and the therapeutic potential of
antisense oligonucleotides.
Br J Cancer
2004;
35
(5):1069
e
68
(15):
34.
181. Minotti G, et al. Anthracyclines: molecular advances and phar-
macologic developments in antitumor activity and cardiotoxicity.
Pharmacol Rev
2004;
6425
e
73.
202. Koukourakis MI, et al. Nuclear expression of human apurinic/
apyrimidinic endonuclease (HAP1/Ref-1) in head-and-neck
cancer is associated with resistance to chemoradiotherapy and
poor outcome.
Int J Radiat Oncol Biol Phys
2001;
91
(6):1166
e
229.
182. Fawcett H, et al. Contribution of reactive oxygen species and
caspase-3 to apoptosis and attenuated ICAM-1 expression by
paclitaxel-treated MDA-MB-435 breast carcinoma cells.
56
(2):185
e
36.
203. Kakolyris S, et al. Expression and subcellular localization of
human AP endonuclease 1 (HAP1/Ref-1) protein: a basis for its
role in human disease.
Histopathology
1998;
50
(1):27
e
Int
J
26.
183. Alexandre J, et al. Novel action of paclitaxel against cancer cells:
bystander effect mediated by reactive oxygen species.
Cancer Res
2007;
Oncol
2005;
27
(6):1717
e
9.
204.
Bobola MS, et al. Apurinic/apyrimidinic endonuclease activity is
elevated in human adult gliomas.
Clin Cancer Res
2001;
33
(6):561
e
7
(11):
7.
184. Burdak-Rothkamm S, Prise KM. New molecular targets in
radiotherapy: DNA damage signalling and repair in targeted and
non-targeted cells.
Eur J Pharmacol
2009;
67
(8):3512
e
8.
205. Simeonov A, et al. Identification and characterization of inhibi-
tors of human apurinic/apyrimidinic endonuclease APE1.
PLoS
ONE
2009;
3510
e
5.
185. Astsaturov I, et al. Synthetic lethal screen of an EGFR-centered
network to improve
625
(1-3):151
e
(6). e5740.
206. Luo M, et al. Redox regulation of DNA repair: Implications for
human health and cancer therapeutic development.
Antioxid
Redox Signal
2010;
4
targeted therapies.
Sci Signal
2010;
(140):ra60.
186. Moeller BJ, Pasqualini R, Arap W. Targeting cancer-specific
synthetic lethality in double-strand DNA break repair.
Cell Cycle
2009;
3
69.
207. Bapat A, Fishel M, Kelley MR. Going ape as an approach to
cancer therapeutics.
Antioxid Redox Signal
2009;
12
(11):1247
e
68.
208. Luo M, et al. Role of the multifunctional DNA repair and redox
signaling protein Ape1/Ref-1 in cancer and endothelial cells:
small-molecule inhibition of the redox function of Ape1.
Antioxid
Redox Signal
2008;
11
:651
e
6.
187. Carden C, Yap TA, Kaye SB. PARP inhibition: targeting the
Achilles' heel of DNA repair to treat germline and sporadic
ovarian cancers.
Curr Opin Oncol
2010;
8
(12):1872
e
80.
188. Darzynkiewicz Z, Traganos F, Wlodkowic D. Impaired DNA
damage response
22
(5):473
e
67.
209. Madhusudan S, Middleton MR. The emerging role of DNA repair
proteins as predictive, prognostic and therapeutic targets in
cancer.
Cancer Treat Rev
2005;
10
(11):1853
e
an Achilles' heel sensitizing cancer to chemo-
therapy and radiotherapy.
Eur J Pharmacol
2009;
e
50.
189. Panda H, et al. Amino acid Asp181 of 5'-flap endonuclease 1 is
a useful target for chemotherapeutic development.
Biochemistry
2009;
625
(1-3):143
e
17.
210. Madhusudan S, Hickson ID. DNA repair inhibition: a selective
tumour targeting strategy.
Trends Mol Med
2005;
31
(8):603
e
48
(42):9952
e
8.
11
(11):503
e
11.
